Tolbutamide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes Tolbutamide belongs to a class of medications called sulfonylureas. Tolbutamide lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Tolbutamide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated). Tolbutamide inhibits both the basal and the cyclic AMP-stimulated protein kinase activities and the IC50 of Tolbutamide is 4 mM, and inhibits glucagon-induced phosphorylation of the bifunctional enzyme protein in a dose-dependent manner. Tolbutamide treatment significantly increases the binding of insulin to isolated adipocytes. The effect is associated with an enhanced response to insulin of the adipose tissue, since the fat cells obtained from animals treated with Tolbutamide convert significantly more glucose to lipids in the presence of insulin than those obtained from the control group .
|Cell lines||C6 glioma cells|
|Preparation method||Before each experiment, incubating C6 glioma cells in serum-free DMEM at 37 °C for at least 24 hours . Tolbutamide (400 μM) is incubated for 24 hours in serum-free medium. Incubations are performed at 37 °C in an atmosphere of 95% air/5% CO2 with 90–95% humidity|
|Incubation time||24 hours|
|Animal models||Male albino Wistar rats (200-300 g)|
|Formulation||Tolbutamide is given as powder and mixed with food.|
|Administration||Tolbutamide is administered orally for 7 days.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Related Potassium Channel Products|
2,2,2-Trichloroethanol is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4).
Nigericin is an antibiotic derived from Streptomyces hygroscopicus, it acts as an H+, K+, Pb2+ ionophore.
ML213 (CID-3111211) is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener, with EC50 values of 230 and 510 nM for KV7.2 and KV7.4, respectively.
CLP290 is a novel, orally available KCC2 modulator, highly selective for KCC2 over related Cl- transporters.
BMS-191011 is a potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.